Numbers

The Numbers

Blue Moon trades where it does because the market can't yet tell whether the 2024 operating loss was a one-shot channel reset or a structural repricing of what a #1 Chinese consumer brand is worth once Douyin and Tmall set the cost of attention. The single metric most likely to rerate or derate this stock is selling & distribution expense as a percent of revenue — it went from 29% (FY2020) to 59% (FY2024) and pulled back to 53% (FY2025). If H1 FY2026 prints below 50%, the balance sheet (zero debt, HK$3.7B net cash) and the 60% gross margin become a re-rating cocktail. If it doesn't, the stock is a melting ice cube with a five-year runway.

Snapshot

Price (HK$) — 2026-04-17

2.96

Market Cap (HK$M)

17,200

Revenue FY2025 (HK$M)

8,409

Quality Score (/100)

Fair Value (HK$, base)

3.00

Zero debt, HK$3.7B of net cash, and a market cap of HK$17.2B means nearly a quarter of the market cap is just the cash on the balance sheet. Enterprise value is roughly HK$13.5B on HK$8.4B of sales — an EV/Sales of 1.6x for a brand that posts 60% gross margins.

Quality Scorecard

**Is this a well-run business that will still be around in 10 years?** The balance sheet says yes — no debt, HK$3.7B cash, Altman Z-score of 7.0 (safe zone is anything above 3.0). The P&L says the jury is still out — two consecutive years of operating losses after a decade of 25%+ margins. Predictability is low because the cost structure has repriced underneath management's feet.

No Results

The composite quality score (42/100) is an average of a great balance sheet and a poor income statement. Readers familiar with branded-consumer frameworks will notice the shape: this is what Colgate or Church & Dwight would look like if they had to retire their CPG playbook on one market and rebuild distribution from scratch.

Revenue & Earnings Power — The Six-Year View

Revenue has grown from HK$7.0B to HK$8.4B over six years — a 3.7% annual rate that understates the story. What actually happened: the company defended volume at any operating-margin cost. The left-hand chart shows operating income collapsed from HK$1,746M to minus HK$355M while revenue went up. The right-hand chart explains why: gross margin stayed flat at ~60%, but operating margin dropped 29 points. Everything that went wrong lives between gross profit and operating profit — in selling & distribution.

The Only Chart That Matters — S&D Ratio

**Every point on this line is about HK$84M of annual operating profit.** S&D at 53% of revenue costs the company ~HK$4.5B a year. At FY2020's 29% ratio it would have cost ~HK$2.4B. The HK$2.1B gap is the entire swing between a 25% operating-margin business and a loss-making one. Watch this line — it is the single best leading indicator for FY2026 earnings.

Revenue Composition — Concentrated, Channel-Dependent

Fabric care is 88% of revenue and has barely moved in five years. Personal hygiene is up 13% in FY2025 but still only 7% of mix. Online revenue peaked in FY2024 at HK$5.1B (60% of sales) and retreated 2.5% in FY2025 as management pulled back from loss-making promotional spend. That offline/online balance around 60/40 is the equilibrium the next P&L turns on.

Cash Conversion & the IPO War Chest

The filings don't publish a line-item cash flow statement, but the change-in-cash tells the story cleanly: in four of the last five years the company burned cash, and total cash is down two-thirds from the IPO high of HK$10.9B. FY2023 lost HK$3.4B of cash against a HK$325M reported profit — the gap is roughly the HK$2.4B special dividend paid that year. FY2024 looked better only because trade receivables fell and the company stopped paying specials. The runway math: at the FY2025 cash outflow of HK$1.6B (operating loss plus ~HK$900M dividend), the company has about 2.5 years before the ordinary dividend has to be cut.

Balance Sheet Health

Total liabilities are trade payables, tax accruals, and lease obligations — no bank borrowings, no bonds. Equity has fallen from HK$11.7B to HK$7.5B through a combination of operating losses, buybacks, and dividends. The Altman Z-score of 7.0 is deep in the safe zone; the distress risk on this name is effectively zero for the next three to four years. That is the reason the stock hasn't been cut in half again.

Valuation — The Six-Year Self-Comparison

Blue Moon only listed in December 2020, so the twenty-year history rule collapses to a six-year self-comparison — which happens to span the full life of the public company. The IPO froth of FY2020 (12.7x sales, 67x earnings) was never rational; strip it out and the useful baseline is FY2021–FY2025. Current P/S at 2.05x is meaningfully below the five-year post-IPO average of 3.02x. Current P/B at 2.29x is right at the post-IPO average. Trailing P/E is undefined (negative earnings) and forward P/E depends on whether you believe FY2026 is a profit year.

Current P/S

2.05

▲ 3.02 5y avg

5y low P/S (FY2023)

1.59

Current P/B

2.29

▲ 2.32 5y avg

The Stock's Journey — IPO to Today

From the IPO-era peak near HK$17 the stock is down about 83%. The FY2023 bottom at roughly HK$2 came as the first operating-margin compression showed up; the FY2024 recovery to HK$4.37 priced in a "channel reset" story; the subsequent slide to HK$2.96 reflects the market's reduced confidence that S&D can get back below 50%. The shape is a classic post-IPO de-rating plus cyclical operating-margin correction — not a capital-structure scare.

Peer Comparison

No Results

Blue Moon trades at the lowest P/S of the group (2.05x vs peer average 3.46x) but also posts the lowest operating margin (-4.2% vs peer range 16–27%). The peer discount is earned: the market is right that this is not yet a Colgate or P&G on earnings quality. The question is whether the gross-margin profile (59.7%, among the highest in the group) plus the balance sheet (zero debt, a rarity in this sector) justify a closer P/S once operating margin stabilizes at the 8–12% this business demonstrated in 2020–2022. Colgate's extreme P/B is a quirk of a share-buyback-driven thin equity base; ignore it when assessing Blue Moon.

Fair Value — Three Scenarios

No Results

At HK$2.96 the stock is effectively at the base case. The distribution is asymmetric up (the bull case requires only that S&D return to FY2022 levels — a normal rather than heroic assumption) but the base case is not supportive enough to own for capital appreciation alone. The incremental investor needs to take a view on whether FY2025's S&D discipline continues.

Bottom Line

What the numbers confirm: the balance sheet is pristine (HK$3.7B net cash, no debt, Altman Z of 7.0) and brand-level economics are intact (60% gross margin, unmoved through six years of channel chaos). What the numbers contradict: the narrative that this is a broken business. It isn't — operating income has been destroyed at a level entirely above gross profit, which means fixing it is a cost-discipline problem, not a pricing-power problem. What to watch next quarter: the H1 FY2026 S&D ratio. Below 50% changes the base case; above 55% triggers a rethink of whether management can resist the Tmall/Douyin promotional cycle at all. Everything else — volume growth, product mix, even the dividend — is downstream of that one line.